These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines. Balasubramanian V; Liu Z; Hirvonen J; Santos HA Adv Healthc Mater; 2018 Jan; 7(1):. PubMed ID: 28570787 [TBL] [Abstract][Full Text] [Related]
29. Anticancer nanomedicines harnessing tumor microenvironmental components. Li Y; Chen Z; Gu L; Duan Z; Pan D; Xu Z; Gong Q; Li Y; Zhu H; Luo K Expert Opin Drug Deliv; 2022 Apr; 19(4):337-354. PubMed ID: 35244503 [TBL] [Abstract][Full Text] [Related]
30. Unraveling the role of Intralipid in suppressing off-target delivery and augmenting the therapeutic effects of anticancer nanomedicines. Islam R; Gao S; Islam W; Šubr V; Zhou JR; Yokomizo K; Etrych T; Maeda H; Fang J Acta Biomater; 2021 May; 126():372-383. PubMed ID: 33774199 [TBL] [Abstract][Full Text] [Related]
31. Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation. Gu W; Meng F; Haag R; Zhong Z J Control Release; 2021 Jan; 329():676-695. PubMed ID: 33022328 [TBL] [Abstract][Full Text] [Related]
33. Targeted Nanomedicines for Cancer Therapy, From Basics to Clinical Trials. Eskandari Z; Bahadori F; Celik B; Onyuksel H J Pharm Pharm Sci; 2020; 23(1):132-157. PubMed ID: 32369437 [TBL] [Abstract][Full Text] [Related]
34. Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines. Durymanov MO; Rosenkranz AA; Sobolev AS Theranostics; 2015; 5(9):1007-20. PubMed ID: 26155316 [TBL] [Abstract][Full Text] [Related]
35. Nanomedicines as cancer therapeutics: current status. Akhter S; Ahmad I; Ahmad MZ; Ramazani F; Singh A; Rahman Z; Ahmad FJ; Storm G; Kok RJ Curr Cancer Drug Targets; 2013 May; 13(4):362-78. PubMed ID: 23517593 [TBL] [Abstract][Full Text] [Related]
36. Evaluating Nanomedicines: Obstacles and Advancements. Swierczewska M; Crist RM; McNeil SE Methods Mol Biol; 2018; 1682():3-16. PubMed ID: 29039088 [TBL] [Abstract][Full Text] [Related]
37. Targeted delivery and enhanced uptake of chemo-photodynamic nanomedicine for melanoma treatment. Huang X; Mu N; Ding Y; Lam HW; Yue L; Gao C; Chen T; Yuan Z; Wang R Acta Biomater; 2022 Jul; 147():356-365. PubMed ID: 35577046 [TBL] [Abstract][Full Text] [Related]
38. Unlocking the Mitochondria for Nanomedicine-based Treatments: Overcoming Biological Barriers, Improving Designs, and Selecting Verification Techniques. Pegoraro C; Domingo-Ortí I; Conejos-Sánchez I; Vicent MJ Adv Drug Deliv Rev; 2024 Apr; 207():115195. PubMed ID: 38325562 [TBL] [Abstract][Full Text] [Related]
39. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Kompella UB; Amrite AC; Pacha Ravi R; Durazo SA Prog Retin Eye Res; 2013 Sep; 36():172-98. PubMed ID: 23603534 [TBL] [Abstract][Full Text] [Related]
40. Protein corona: challenges and opportunities for targeted delivery of nanomedicines. Jiang Z; Chu Y; Zhan C Expert Opin Drug Deliv; 2022 Jul; 19(7):833-846. PubMed ID: 35738018 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]